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Background: Neurite outgrowth is an important aspect of neuronal plasticity and regeneration after neuronal
injury. Alpha-lipoic acid (LA) has been used as a therapeutic approach for a variety of neural disorders.We recently
reported that LA prevents local anesthetics-induced neurite loss. In this study, we hypothesized that LA
administration promotes neurite outgrowth. Methods: To test our hypothesis, we treated mouse neuroblastoma
N2a cells and primary neurons with LA. Neurite outgrowth was evaluated by examination of morphological
changes and by immunocytochemistry for β-tubulin-3. ROS production was examined, as were the
phosphorylation levels of ERK and Akt. In separate experiments, we determined the effects of the inhibition of
ERK or PI3K/Akt as well as ROS production on LA-induced neurite outgrowth. Results: LA promoted signiﬁcantly
neurite outgrowth in a time- and concentration-dependent manner. LA stimulation signiﬁcantly increased the
phosphorylation levels of both Akt and ERK and transiently induced ROS production. PI3K/Akt inhibition did not
affect LA-induced neurite outgrowth. However, the inhibition of ERK activation completely abolished LA-induced
neurite outgrowth. Importantly, the prevention of ROS production by antioxidants attenuated LA-stimulated ERK
activation and completely abolished LA-promoted neurite outgrowth. Conclusion: Our data suggest that LA
stimulates neurite outgrowth through the activation of ERK signaling, an effectmediated through a ROS-dependent
mechanism.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Neurite outgrowth is an important aspect of neuronal plasticity and
regeneration in neuropathological conditions and neural injury [1–3].
Neurite outgrowth is also essential for neuronal pathﬁnding and the
establishment of synaptic connections during development [1].
Alpha-lipoic acid (LA) is a naturally occurring dithiol compound
synthesized enzymatically in mitochondrion from octanoic acid. LA has
been described as a potent biological antioxidant and is used to treat
various neural disorders, including pain disorders [4], Alzheimer's [5]rve growth factor; LA, α-lipoic
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l rights reserved.and Parkinson's diseases [6], diabetic polyneuropathy [7] and chemo-
therapy neuropathy [8]. In addition, LA has been shown to improve
spatialmemory and temporalmemory in ApoE4 transgenicmice [9] and
to reduce the potentiation of noise-induced hearing loss [10]. The
mechanisms by which LA exerts its neuroprotective effects involve
antiapoptotic properties mediated by the inhibiting of proapoptotic
signaling [6] and the activation of antiapoptotic signaling [5,11]. LA has
also been shown to prevent mitochondrial damage [8]. We have
previously reported that LA prevents local anesthetics-triggered neurite
loss and neuron death [11]. Whether LA stimulates neurite outgrowth,
however, is unknown.
Wehave recently demonstrated that LA treatment activates PI3K/Akt
signaling in neurons [11]. We also found that LA activates ERK signaling
(datanot shown).Activationof theERKandPI3K/Akt signalingpathways
has been reported to regulate neuronal differentiation [12–14] and to
protect neurons from drug-induced injury [5,11]. In addition, the
activation of ERK is required for NGF-stimulated neurite outgrowth in
PC12 cells [15–17]. Collectively, these data suggest that both ERK and
PI3K/Akt signaling are involved in neurite outgrowth.
In the present study, we examined the effect of LA treatment on
neurite outgrowth in mouse neuroblastoma N2a (N2a) cells and rat
primary hippocampal neurons. To the best of our knowledge, we are
the ﬁrst to report that LA promotes neurite outgrowth and that this
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signaling. More importantly, LA administration induces a transient
and moderate production of ROS in N2a cells. The inhibition of ROS
production attenuates the LA-induced activation of ERK and com-
pletely abolishes LA-induced neurite outgrowth.
2. Materials and methods
2.1. Chemicals
LA, 2',7'-dichloroﬂuorescein diacetate (DCFH-DA), N-acetylcysteine
(NAC), diphenyleneiodonium chloride (DPI), PD98059 (PD), SB202190,
SP600125 and wortmannin (WM) were purchased from Sigma-Aldrich
(St. Louis, MO). Hoechst 33342 reagent, minimum essential medium
(MEM), neurobasal medium, fetal calf serum (FCS) and B27 supplement
were purchased from Invitrogen Life Technology (Carlsbad, CA). Primary
antibodies for total Akt and total ERK, phospho-Akt (p-Akt) andphospho-
ERK (p-ERK) were obtained from Cell Signaling Technology (Beverly,
MA). A primary antibody against β-tubulin-3 was purchased from R&D
Systems, Inc. (Minneapolis, MN). Normal goat serum (NGS) and
antibodies against IgG conjugated with horseradish peroxidase (HRP)
or Cy3 were purchased from Vector Labs (Burlingame, CA). Complete
protease inhibitor cocktail was purchased from Roche (Mannheim,
Germany). MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide] reagentwas purchased from Bio Besic, Inc. (Markham, Ontario,
Canada). The BCA protein assay kit and SuperSignal West Pico
chemiluminescent substrate were obtained from Pierce (Rockford, IL).
Triciribine (API) was obtained from Kangcheng BioTtech (Shanghai,
China).
2.2. Cell culture
N2a cells were plated in 60-mm dishes at a density of 3×105 cells/
dish and grown in MEM supplemented with 10% FCS. Twenty-four
hours later, cell medium was changed to MEM containing 5% FCS and
subjected to treatment.
Primary hippocampal neurons were isolated from neonatal
Sprague–Dawley rats and cultured in Neurobasal medium containing
B27 supplement using methods described previously [11,16]. After 12
h, neurons were subjected to LA stimulation (500 μM). n=3/group.
For theexperiments using inhibitors forMEK/ERK (PD98059, 40 μM),
p38 MAPK (SB202190, 10 μM), JNK (SP600125, 10 μM), PI3K (WM,
500 nM) and Akt (API, 1 mM), N2a cells were pretreated with these
inhibitors 30 min prior to LA (500 μM) administration. For the experi-
ments involving antioxidants, N2a cells were pretreated with NAC
(20 mM) or DPI (10 μM) 30 min prior to LA (500 μM) administration.
2.3. Measurement of neurite outgrowth
For experimental analyses of the dose– and time–response of
neurite outgrowth in N2a cells, cells were treated with LA at various
concentrations (0, 100, 300 or 500 μM) for different time periods (24,
36, 48 and 60 h). Neurite outgrowth was then observed under a
phase-contrast light microscope (Axiovert 200, Zeiss Ltd., Germany)
at a magniﬁcation of 200×. A neurite was deﬁned as a process with
length greater than twofold the cell body diameter and possessing a
terminal growth cone, as described previously [18]. The percentage of
cells with neurites was calculated by counting 300–400 cells per well
in randomly chosen ﬁelds. n=3–4/group.
Measurements of neurite outgrowth in primary hippocampal
neurons were made under a phase-contrast light microscope 24 and
36 h following LA stimulation. For experiments using inhibitors of ROS
production (NAC, 20 mM) or MEK (PD98059, 40 μM), primary
neurons were pretreated with these inhibitors 30 min prior to LA
(500 μM) administration, respectively. Neurite length was measuredin 5–10 random ﬁelds in each well at a magniﬁcation of 200×. Images
were analyzed using image pro-plus software. n=3/group.
2.4. Fluorescent immunocytochemistry
After 60 h (for N2a cells) or 36 h (for primary hippocampal neurons)
treatmentwith LA, cellswereﬁxed in 50%methanol and 50% acetone for
15 min. After blocking with 7.5% NGS for 1 h at room temperature, the
primaryβ-tubulin-3 antibody (1:500)was applied to the cells overnight
at 4 °C. Subsequently, a Cy3-conjugated secondary antibody (1:100)
was added to the cells for 2 h at room temperature. Hoechst 33342 was
used to counter-stain the nuclei. Images were observed under a
ﬂuorescent microscope (Zeiss Ltd., Germany). n=3/group.
2.5. Determination of intracellular ROS levels
ROS levels in N2a cells were determined using a DCFH assay in the
following treatment groups: (1) N2a cells treated with at different
concentrations of LA (0, 100, 300 and 500 μM) for 30 min (n=4/group)
and (2)N2a cells treatedwith LA (500 μM) for 30 min in the presence or
absence of antioxidants (NAC 20 mM or DPI 10 μM; n=4–6/group).
DCFH-DA is a cell-permeable compound. When it enters cells, the
acetate group is cleaved by cellular esterases, and non-ﬂuoresent
DCFH is trapped inside. Following oxidation by ROS, DCFH yields the
ﬂuorescent product DCF. Therefore, DCFH-DA is an ROS-sensitive
probe that can detect oxidative activity in living cells. In the present
study, cells were incubated with DCFH-DA (10 μM) for 30 min in the
dark. Data were collected by a ﬂuorometer equipped with a 24-well
plate reader (Synergy HT, BIO-TEK, USA) at an excitation/emission
wavelength of 485/530 nm.
2.6. Cell proliferation
Cell proliferation was examined using a MTT assay. N2a cells were
treated with LA at various concentrations (500, 1000 or 1500 μM).
MTT assays were performed 24, 40 and 60 h following LA treatment,
respectively, according to manufacturer's instructions. At the end of
LA treatment, cells were incubated with MTT (0.5 mg/ml) for 4 h. The
crystals that formed were solubilized in 100 μl of DMSO, and the color
was read photometrically at 570 nm on a Synergy HT plate reader
(Synergy HT, Bio-Tek, USA; n=5/group).
2.7. Western blot
Phosphorylation levels of Akt, ERK, p38 MAPK and JNK were
examined by Western blot in N2a cells that received the following
treatments: (1) N2a cells treatedwith LA (500 μM) for 0.5, 1, 3, 6, 12, 24
and 36 h (n=3/group) and (2) N2a cells treated with LA (500 μM) for
30 min in the presence or absence of an antioxidant (NAC), MEK
inhibitor (PD98059), p38 MAPK inhibitor (SB202190), JNK inhibitor
(SP600125), PI3K inhibitor (WM) or Akt inhibitor (API). n=3–7/group.
Western blots were performed as previously described [11]. Brieﬂy,
equal amounts of protein extracts were separated on a 10% SDS-PAGE
gel and transferred onto an immobilon-p membrane (Milipore Corp).
Following the blocking step, membranes were incubated with primary
antibodies at 4 °C overnight, followed by incubation with a secondary
antibody. The same membranes were also probed with anti-α-tubulin
for loading control. Proteins were detected with an ECL kit, and signals
were quantiﬁed using scanning densitometry.
2.8. Statistical analyses
Results are expressed as means±standard deviation (x±SD).
Comparison data between groups was performed using one-way
analysis of variance (ANOVA). Tukey's procedure for multiple range
tests was performed. Pb0.05 was considered statistically signiﬁcant.
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3.1. LA induces neurite outgrowth in N2a cells and primary neurons
We examined the effects of different doses of LA and periods of
treatment on neurite outgrowth in N2a cells. Fig. 1A shows that LA-
stimulated neurite outgrowth in N2a cells in a time- and dose-
dependent manner. Following treatment with LA for 24 h, the number
of neurite-bearing cells was signiﬁcantly increased in the cells treatedFig. 1. LA promotes neurite outgrowth. (A) LA induces neurite outgrowth of N2a cells in
concentrations (100, 300 and 500 μM) for different periods (24, 36, 48 and 60 h), respectiv
bearing cells were counted. *Pb0.01 and #Pb0.05 vs. time-matched controls, n=3/group.
measured in neurons following incubation with LA (500 μM) for 24 and 36 h. Upper panel re
as visualized by immunostaining for β-tubulin-3. *Pb0.01 and #Pb0.05, n=3/group.with 500 μMof LA but did not increase in the cells treated with100 μM
and 300 μM of LA, when compared with untreated control cells.
However, when compared with time-matched, untreated cells, the
number of neurite-bearing cells increased 0.86-, 1.80- and 4.41-fold
following stimulation with LA for 60 h at concentrations of 100, 300
and 500 μM, respectively (Pb0.01 or 0.05). Based on these data, we
used an LA concentration of 500 μM in the subsequent experiments.
We also examined the effect of LA on neurite outgrowth in primary
hippocampal neurons. Fig. 1B shows that neurite length wasa dose- and time-dependent manner. N2a cells were stimulated with LA at various
ely. Cell morphology was observed under a light microscope (200×) and the neurite-
(B) LA promotes neurite growth in primary hippocampal neurons. Neurite length was
presents neurite morphology of neurons treated with LA for 36 h or untreated neurons,
830 X. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 827–838signiﬁcantly increased following LA treatment for 24 h (Pb0.05) and
36 h (Pb0.01), respectively, when compared with time-matched
untreated cells. The upper panel shows the representative morphol-
ogy of untreated neurons or those treated with LA for 36 h.3.2. LA increases phosphorylation of Akt and ERK in N2a cells
To determine whether PI3K/Akt and/or ERK signaling is involved
in LA-mediated neurite outgrowth in neurons, we examined the
phosphorylation levels of Akt and ERK in N2a cells with or without LA
treatment. As shown in Fig. 2, LA treatment signiﬁcantly increased
both Akt and ERK phosphorylation in a time-dependent manner. The
levels of phospho-Akt were signiﬁcantly increased by 206.4%, 64.1%,
92.1%, 162.3%, 187.8%, and 210.4% following LA treatment for 0.5, 1, 3,
6, 24, and 36 h, respectively, when compared with untreated cells
(Pb0.01). The levels of phospho-ERK were signiﬁcantly increased by
229.4%, 162.5%, 86.3%, 75.1%, 154.0%, and 189.2% following LA
treatment for 0.5, 1, 3, 6, 24, and 36 h, respectively, when compared
with untreated control cells (Pb0.01 or 0.05).3.3. PI3K/Akt inhibition does not affect LA-induced neurite outgrowth in
N2a cells
To determine whether the activation of PI3K/Akt signaling is
involved in LA-induced neurite growth, we treated N2a cells with
WM, a PI3K inhibitor, 30 min prior to LA administration. Fig. 3A shows
that WM treatment prevented LA-induced Akt phosphorylation.
However, WM administration did not affect LA-induced neurite
outgrowth (Fig. 3B). We next pretreated N2a cells with API, a
selective Akt inhibitor, 30 min prior to LA administration. As shown in
Fig. 3C, API administration signiﬁcantly reduced LA-induced phospho-
Akt by 69.1%. However, similar to WM treatment, API administration
did not affect the LA-induced increase in the number of neurite-
bearing cells (Fig. 3D). These data suggest that activation of PI3K/Akt
signaling is not involved in LA-induced neurite outgrowth.
Interestingly, the administration of eitherWM or API to LA-treated
N2a cells signiﬁcantly increased the levels of phospho-ERK (Fig. 3E, F).Fig. 2. LA increases the levels of phospho-ERK and phospho-Akt in N2a cells. N2a cells we
prepared for Western blot analysis. *Pb0.01 and #Pb0.05 vs. 0 h group, n=3/group.These data suggests that there is an interaction between PI3K/Akt
signaling and the ERK pathway.
3.4. LA-induced neurite outgrowth requires activation of ERK
Wenext examined the role of ERKpathwayactivationon LA-induced
neurite outgrowth.We treatedN2a cellswith anERK inhibitor, PD98059
(PD), 30 min prior to LA administration. As shown in Fig. 4A, PD
administration signiﬁcantly reduced LA-induced increases in the levels
of phospho-ERK by 76.4% when compared with cells treated with LA
alone. PD administration also reduced the levels of phospho-ERK by
68.2% in LA-untreated cells. Fig. 4B shows that the inhibition of ERK
activation by PD administration completely abolished LA-induced
neurite outgrowth. These data suggest that LA-induced neurite
outgrowth is mediated by the activation of ERK signaling.
We also examined whether the other two members of the MAPK
family, p38 MAPK and JNK, are involved in LA-induced neurite
outgrowth. As shown in Fig. 4C, p38 MAPK and JNK phosphorylation
levels in LA-treated N2a cells were increased by 97.5% and 73.8%,
respectively, when compared with untreated controls (Pb0.01 or
0.05). Treatment with SB202190 and SP600125 signiﬁcantly sup-
pressed the LA-induced activation of p38 MAPK and JNK, respectively
(Fig. 4D, F). The inhibition of JNK abolished LA-induced neurite
outgrowth (Fig. 4E), whereas the inhibition of p38 MAPK did not
(Fig. 4G).
3.5. LA-induced neurite outgrowth requires ROS production in N2a cells
We examined how LA administration activates ERK signaling. It
has been shown that transiently produced ROS could serve as a
signaling molecule. Moderate production of ROS has been reported to
be essential for neuronal outgrowth and differentiation [19,20]. We
therefore examined whether LA administration induces ROS produc-
tion in N2a cells. We treated N2a cells with 100, 300 or 500 μM of LA
for 30 min and measured ROS production. As shown in Fig. 5A,
treatment with these concentrations of LA increased ROS production
by 18.2%, 39.2%, and 44.0%, respectively, when compared with
untreated cells (Pb0.01). The upper panel of Fig. 5C showsre challenged with LA (500 μM) for 0.5, 1, 3, 6, 12, 24 and 36 h. Protein extracts were
Fig. 3. Inhibition of PI3K/Akt does not affect LA-induced neurite outgrowth. (A) WM inhibits LA-induced Akt activation. N2a cells were pretreated with WM 30 min prior to LA
exposure (500 μM). Thirty minutes following LA stimulation, cellular extracts were prepared and subjected to Western blot analysis. *Pb0.01, n=3/group. (B) WM has no effect on
LA-induced neurite outgrowth. N2a cells were pretreated with WM 30 min prior to LA exposure (500 μM). Sixty hours following LA treatment, morphology was examined and
neurite-bearing cells were counted under a light microscope (200×). *Pb0.01, n=3/group. Upper panel shows neurites visualized by immunostaining with β-tubulin-3 (n=3/
group). (C) API inhibits LA-induced Akt activation. N2a cells were pretreated with API 30 min prior to LA exposure (500 μM). Thirty minutes following LA stimulation, cellular
extracts were prepared and subjected to Western blot analysis. *Pb0.01, n=3–6/group. (D) API has no effect on LA-induced neurite outgrowth. N2a cells were pretreated with API
30 min prior to LA exposure (500 μM). Sixty hours following LA treatment, morphology was examined and neurite-bearing cells were counted under a light microscope (200×).
*Pb0.01, n=3/group. Upper panel shows the neurites visualized by immunostaining with β-tubulin-3 (n=3/group). (E, F) Inhibition of PI3K/Akt signaling activates ERK. N2a cells
were pretreated with WM or API 30 min prior to LA exposure (500 μM). Thirty minutes following LA stimulation, cellular extracts were prepared and subjected to Western blot
analysis. *Pb0.01, n=3–6/group.
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Fig. 3 (continued).
832 X. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 827–838representative images of DCF ﬂuorescence in cells treated with or
without 500 μM LA. DCF ﬂuorescence was stronger in LA-treated cells
than in untreated cells.
Because excessively high levels of ROS are detrimental to the cell,
we used a MTT assay to examine whether higher concentrations of LA
could inhibit cell proliferation. As shown in Fig. 5B, 500 μM of LA did
not signiﬁcantly modify cell proliferation when compared with time-
matched controls at all measured time points. However, proliferation
was signiﬁcantly lower in cells treatedwith 1000 or 1500 μMLAwhen
compared with time-matched controls (Pb0.01).
To determine the role of ROS production in LA-induced neurite
outgrowth, we treated N2a cells with two antioxidants, NAC or DPI,
30 min prior to LA administration. Fig. 5C shows that either NAC or
DPI administration signiﬁcantly prevented LA-induced ROS produc-
tion. Importantly, LA-induced neurite outgrowth was completely
abolished by both NAC and DPI pretreatment (Fig. 5D). Fig. 5E shows
that NAC administration signiﬁcantly decreased LA-induced phospho-
ERK levels by 69.3% when compared with LA-treated, NAC-untreated
cells. These data suggest that LA-induced neurite outgrowth requires
moderate ROS production, which serves as a signaling molecule for
the activation of ERK.
3.6. LA-induced increases in neurite length in primary neurons is
inhibited by antioxidant and ERK inhibitor
Finally, we examined whether antioxidant or ERK inhibitor could
suppress the observed LA-induced increase in neurite length in
primary neurons (Fig. 1B). Primary hippocampal neurons were
pretreated with the antioxidant, NAC, or the MEK/ERK inhibitor, PD,
30 min prior to LA exposure. As shown in Fig. 6, treatment with either
NAC or PD blocked the LA-induced increase in neurite length
(Pb0.01). The upper panel shows representative neurite morphology
of cells treated with LA for 36 h in the presence or absence of NAC or
PD.
4. Discussion
The primary ﬁndings of the present study are that treatment with
LA promotes neurite outgrowth in both primary hippocampal
neurons and mouse neuroblastoma N2a cells. Moreover, LA stimula-
tion activated both PI3K/Akt and ERK signaling. However, the
inhibition of ERK activation, but not PI3K/Akt, abolished LA-
stimulated neurite growth. We conﬁrmed that LA-induced ERK
activation was mediated by production of ROS, which serves as a
signaling molecule. Inhibition of ROS production via antioxidantadministration completely abolished LA-induced neurite outgrowth
and ERK activation. Our results suggest that the observed LA-induced
neurite outgrowth was mediated by the activation of ERK signaling
through a ROS-dependent mechanism.
It has long been noted that axonal and synaptic damage can precede
the loss of neuronal cell bodies by months [21,22]. Recently, it has
become clear that the loss of major synapses and axons occurs long
before the appearance of symptoms in most, and possibly all,
neurodegenerative diseases, including Alzheimer's, Parkinson's, Hun-
tington's, motoneuron and prion diseases [21,22]. We have previously
reported that LA treatment prevents drug-induced neurite loss and
neuronal death in N2a cells [11], suggesting that neurite protection
could be apotentialmechanismmediating LA-inducedneuroprotection.
Indeed, we demonstrate in the present study that prolonged LA
exposure of both primary hippocampal neurons and N2a cells
signiﬁcantly enhances neurite outgrowth. Recent studies have shown
that LA has neuroprotective properties in both patients and animal
models with various neural diseases, including pain disorders [4],
Alzheimer's disease [5], Parkinson's disease [6] and diabetic polyneuro-
pathy [23]. Interestingly, LA has been considered as a novel therapeutic
approach formultiple sclerosis and other chronic inﬂammatorydiseases
of the central nervous system [24]. The mechanisms of LA's protective
effects involve inhibiting T-type calcium channels in the pain pathway
[4], reducing oxidative damage and improving cognitive performance
[25,26]. In addition, LAmay inhibit ASK1/Daxx signaling [6] and activate
PI3K/Akt or PI3K/PKG/ERK pathways [5,11]. However, nothing is known
regardingwhether these signalingpathways are involved in LA-induced
neurite outgrowth.
The activation of the PI3K/Akt signaling pathway has been
reported to play a role in mediating neuronal differentiation [12–
14] and in protecting neurons from drug-induced damage [5,11]. In
the present study, we observed that LA administration signiﬁcantly
increased the levels of phospho-Akt in N2a cells, suggesting that LA
stimulation activated the PI3K/Akt signaling pathway. However,
pharmacological inhibition, either by WM to inhibit PI3K activity or
by API to prevent Akt phosphorylation, did not affect LA-induced
neurite outgrowth. These data indicate that PI3K/Akt signaling
activation is not involved in LA-induced neurite outgrowth in N2a
cells. Interestingly, we observed that PI3K/Akt inhibition signiﬁcantly
increases levels of ERK phosphorylation, indicating that there may be
an interaction between PI3K/Akt and ERK. This ﬁnding also suggests
that the activation of ERK signaling may be involved in LA-induced
neurite outgrowth.
Indeed, we observed that LA administration increased levels of
ERK phosphorylation in N2a cells, suggesting that LA treatment
833X. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 827–838activated ERK signaling. To determine the role of ERK activation in LA-
induced neurite outgrowth, we treated cells with an ERK-speciﬁc
inhibitor 30 min prior to LA administration. We observed that
administration of the ERK inhibitor prevented LA-induced ERK
phosphorylation. More signiﬁcantly, ERK inhibition completely
abolished LA-induced neurite outgrowth in primary neurons and
N2a cells. These data provide strong evidence that the activation of
ERK is required for LA-stimulated neurite outgrowth. Our observation
is supported by other studies showing the involvement of ERK
signaling in neuronal differentiation. For example, NGF- and human
chorionic gonadotropin (hCG)-stimulated neurite outgrowth in PC12
cells has been shown to activate ERK signaling [15,16]. Moreover, the
inhibition of ERK activation prevents both NGF- and hCG-stimulated
neurite outgrowth [17]. Collectively, these data suggest that ERKFig. 4. Inhibition of MEK/ERK abolishes LA-induced neurite outgrowth. (A) PD98059 (PD) sup
LA exposure (500 μM). Thirty minutes following LA stimulation, cellular extracts were pr
abolishes LA-induced neurite outgrowth. N2a cells were pretreated with PD 30 min prior to
and the neurite-bearing cells were counted under a light microscope (200 ×). *Pb0.01, n=3
(n=3/group). (C) LA treatment induces activation of p38 MAPK and JNK. N2a cells were t
western blot analysis. *Pb0.01 and #Pb0.05, n=3/group. (D, E) Inhibition of JNK suppresses L
LA exposure (500 μM). JNK activationwas examined 30 min following LA treatment (D). Mor
(200×) following a 60-h treatment with LA (E). Neurites were visualized by immunostaini
MAPK has no effect on LA-induced neurite outgrowth. N2a cells were pretreated with SB2
30 min following LA treatment (F). Morphology was examined and neurite-bearing cells w
Neurites were visualized by immunostaining against β-tubulin-3 (G). *Pb0.01, n=3/groupactivation is essential for neurite outgrowth. However, the mecha-
nism by which LA activates the ERK signaling pathway is still unclear.
ROS can be generated by multiple sources, including NADPH
oxidases, xanthine oxidase, uncoupled NO synthase andmitochondria
[27]. NADPH oxidases produce ROS in normoxic conditions, whereas
other enzymes produce ROS only following its conversion to a
dysfunctional state [27]. DPI is an inhibitor of NADPH oxidases,
xanthine oxidase and uncoupled NO synthase [27]. In the present
study, we observed that DPI inhibited LA-stimulated ROS production
in N2a cells grown in normoxic conditions, suggesting the involve-
ment of NADPH oxidases in LA-induced ROS production.
Numerous studies have shown that LA mediates its antioxidant
effects by scavenging reactive oxygen and nitrogen species in vitro.
However, there is little evidence showing that this occurs in vivo orpresses LA-induced activation of ERK. N2a cells were pretreatedwith PD 30 min prior to
epared and subjected to Western blot analysis. *Pb0.01, n=3–6/group. (B) PD98059
LA exposure (500 μM). Sixty hours following LA treatment, morphology was examined
/group. Upper panel shows neurites visualized by immunostaining against β-tubulin-3
reated with LA (500 μM) for 30 min. Cellular extracts were prepared and subjected to
A-induced neurite outgrowth. N2a cells were pretreated with SP600125 30 min prior to
phology was examined and neurite-bearing cells were counted under a lightmicroscope
ng against β-tubulin-3 (E). *Pb0.01 and #Pb0.05, n=3/group. (F, G) Inhibition of p38
02190 30 min prior to LA exposure (500 μM). Activation of p38 MAPK was examined
ere counted under a light microscope (200×) following 60-h treatment with LA (G).
.
Fig. 4 (continued).
834 X. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 827–838that radical scavenging contributes to the primary mechanism of
action of LA [28,29]. Mounting evidence indicates that LA may exhibit
antioxidant and prooxidant properties [30,31]. The mechanisms
underlying the positive and negative effects of LA on ROS production
are not yet clear. However, Dicter et al. suggest that LA acts as a
powerful antioxidant only following long-term incubation, whereas itmay function as a prooxidant following short-term incubation and
rapid uptake by tissue or cells [32]. The beneﬁcial role of LA
supplementation on the organismal and cellular levels could be due
to its mild prooxidant activity, which could, in turn, lead to cellular
adaptation against oxidative stress by increasing redox capacity (e.g.,
glutathione synthesis) [31,32]. Indeed, the LA-mediated suppression
Fig. 5. LA-induced ROS generation is required for LA-induced neurite outgrowth. (A) LA increases ROS generation. ROS levels were determined using the DCFH assay following
treatment with LA (0, 100, 300 and 500 μM) for 30 min. *Pb0.01 vs. 0 μMgroup, n=4/group. (B) Effect of LA on cell proliferation. Cell proliferation was measured using a MTT assay.
N2a cells were treated with LA at different concentrations (500, 1000 or 1500 μM). Untreated cells served as controls. The MTT assay was performed at 24, 40 and 60 h following LA
treatment, respectively. Note that treatment with 500 μM LA did not signiﬁcantly alter cell proliferation. Upper panel shows the representative morphology of N2a cells treated with
LA for 48 h. *Pb0.01, n=5/group. (C) Antioxidants abolish the LA-induced ROS generation. Cells were treated with two antioxidants, NAC and DPI, 30 min prior to LA administration
(500 μM). ROS levels were determined using a DCFH assay following 30 min treatment with LA. Upper panel shows representative images of DCF ﬂuorescence in N2a cells that
treated with LA for 30 min in the presence or absence of NAC. *Pb0.01 and #Pb0.05, n=4–6/group. (D) Treatment with antioxidants abolishes LA-induced neurite outgrowth. N2a
cells were treated with NAC or DPI 30 min prior to LA administration (500 μM). Sixty hours following LA treatment, morphology was examined and neurite-bearing cells were
counted under a light microscope (200×). *Pb0.01, n=3–4/group. Upper panel shows neurites visualized by immunostaining with β-tubulin-3 (n=3/group). (E) Treatment with
antioxidants inhibits LA-induced activation of ERK. N2a cells were pretreated with NAC 30 min prior to LA administration. The levels of phospho-ERK were examined 30 min
following LA administration. *Pb0.01 and #Pb0.05, n=4–7/group.
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Fig. 5 (continued).
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shown to require pre-incubation of PC12 cells with LA for 12–24 h
[31]. Recent evidence suggests that the therapeutic and anti-aging
effects of LA are due to its modulation of signal transduction and gene
transcription, both of which improve the antioxidant status of the cell.
Paradoxically, this likely occurs via prooxidant mechanisms, not by
radical scavenging [28–30]. ROS has not only been shown to be toxic
but also to function as a signalingmolecules [28,32,33]. We and others
have reported that the administration with LA moderately increases
cellular ROS levels [11,32,34]. These moderately enhanced ROS levels
were positively correlated with an LA-mediated improvement of
neuronal survival [11,35,36]. In the present study, we observed that
LA administration induces transient moderate ROS production in N2a
cells. However, treatment of the cells with antioxidants prior to LA
administration signiﬁcantly attenuates LA-induced ERK activation.
More importantly, administration of antioxidants completely abol-
ished LA-stimulated neurite outgrowth in primary neurons and N2a
cells. These data suggest that LA induces the moderate production ofROS, which in this content serve as signalingmolecules and lead to the
activation of ERK. The activation of this pathway results in neurite
outgrowth. Our observation is supported by other studies [1,18–20].
For example, NGF- and CoCl2-induced neurite outgrowth in PC12 cells
requires the production of ROS [19,20]. When this evidence is
considered as a whole, it suggests that transient, moderate generation
of ROS by LA is required for LA-stimulated neurite outgrowth, which is
mediated through the activation of ERK signaling.
In summary, this study demonstrates that LA stimulates neurite
outgrowth in both primary hippocampal neurons and mouse
neuroblastoma N2a cells. The mechanisms by which this occurs
involve the LA-induced activation of ERK signaling through a ROS-
dependent mechanism.Conﬂict of interest statement
The authors declare that there are no conﬂicts of interest.
Fig. 6. LA-induced increases in neurite length of primary hippocampal neurons is inhibited by antioxidant and ERK inhibitor. Primary hippocampal neurons were pretreated with the
antioxidant, NAC, or the MEK/ERK inhibitor, PD, 30 min prior to LA exposure. Neurite length was measured following incubation with LA (500 μM) for 24 and 36 h. The upper panel
shows representative neurite morphology visualized by β-tubulin-3 immunostaining of neurons treated with LA for 36 h. *Pb0.01, n=3/group.
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